找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cell Culture Engineering and Technology; In appreciation to P Ralf P?rtner Book 2021 The Editor(s) (if applicable) and The Author(s), under

[復制鏈接]
樓主: Autopsy
11#
發(fā)表于 2025-3-23 11:31:15 | 只看該作者
12#
發(fā)表于 2025-3-23 14:36:51 | 只看該作者
Practical Considerations for the Scale-Up of Chinese Hamster Ovary (CHO) Cell Cultures the fastest-growing segment of the global biopharmaceutical market. During process development, scale-up is done stepwise from micro-bioreactors or shake flasks, to benchtop bioreactors, passing by pilot-scale platforms before finally being implemented in industrial-scale vessels. However, achievin
13#
發(fā)表于 2025-3-23 21:19:10 | 只看該作者
Intensified and Continuous mAb Production with Single-Use Systemsic and autoimmune diseases. Their commercial production processes are mainly based on Chinese hamster ovary (CHO) suspension cells, which are currently cultivated in fed-batch mode at cubic meter scale. The annually growing market for therapeutic mAbs and the pressure on producers to reduce their ma
14#
發(fā)表于 2025-3-24 00:22:13 | 只看該作者
Mathematical Modelling of Cell Culture Processesdels can be used to simulate mammalian cells. Modelling of bioprocesses largely benefit from including kinetics, which reflects the influence of metabolites or other factors on the process variables. Due to the complexity of the kinetic models, with the challenges of determining the kinetic equation
15#
發(fā)表于 2025-3-24 04:13:41 | 只看該作者
16#
發(fā)表于 2025-3-24 09:55:49 | 只看該作者
Filtering of spatio-temporal fields, these challenges. This chapter describes the current and future cell engineering strategies to achieve high therapeutic protein productivity with desired product quality in biotechnologically important mammalian cell lines.
17#
發(fā)表于 2025-3-24 13:30:22 | 只看該作者
18#
發(fā)表于 2025-3-24 18:40:34 | 只看該作者
Next-Generation Cell Engineering Platform for Improving Recombinant Protein Production in Mammalian these challenges. This chapter describes the current and future cell engineering strategies to achieve high therapeutic protein productivity with desired product quality in biotechnologically important mammalian cell lines.
19#
發(fā)表于 2025-3-24 21:54:40 | 只看該作者
20#
發(fā)表于 2025-3-25 02:09:08 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-20 19:40
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
靖西县| 建昌县| 霍州市| 河津市| 平和县| 呈贡县| 揭阳市| 新蔡县| 平陆县| 灌云县| 开阳县| 蓬溪县| 灵璧县| 通渭县| 沂水县| 日土县| 新竹市| 阜阳市| 宜昌市| 会同县| 墨玉县| 鸡西市| 安庆市| 新田县| 明光市| 霍林郭勒市| 保山市| 台东市| 九江县| 谷城县| 美姑县| 都兰县| 视频| 宁晋县| 吉安市| 竹山县| 遂平县| 昭平县| 浦城县| 梁山县| 三门县|